Zobrazeno 1 - 10
of 27
pro vyhledávání: ''
Autor:
Eli Muchtar, Prashant Kapoor, Lisa Hwa, David Dingli, Taxiarchis Kourelis, Amie Fonder, Morie A. Gertz, Matthew Ho, Shaji Kumar, Suzanne R. Hayman, Saurabh Zanwar, Francis K. Baudi, Nelson Leung, Robert A. Kyle, Miriam Hobbs, Martha Q. Lacy, Angela Dispenzieri, Rahma Warsame, S. Vincent Rajkumar
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 9, Pp 1-10 (2021)
Blood Cancer Journal
Blood Cancer Journal
The optimal duration of lenalidomide maintenance post-autologous stem cell transplant (ASCT) in Multiple Myeloma (MM), and choice of therapy at relapse post-maintenance, need further evaluation. This retrospective study assessed outcomes of patients
Autor:
Betsy LaPlant, Thomas M. Habermann, Ivana N. Micallef, Luis F. Porrata, Rebecca L. King, Yucai Wang, Stephen M. Ansell, William R. Macon, Patrick B. Johnston, David J. Inwards, Thomas E. Witzig, Sanjal Desai, Grzegorz S. Nowakowski
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 9, Pp 1-7 (2021)
Blood Cancer Journal
Blood Cancer Journal
Diffuse large B-cell lymphoma (DLBCL), either concurrent with or transformed from follicular lymphoma (FL) is often excluded from clinical trials. Lenalidomide has response rates of 45% in relapsed transformed DLBCL. Herein we present an analysis of
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 6, Pp 1-9 (2021)
Blood Cancer Journal
Blood Cancer Journal
In 1957, Hillestad et al. defined acute promyelocytic leukemia (APL) for the first time in the literature as a distinct type of acute myeloid leukemia (AML) with a “rapid downhill course” characterized with a severe bleeding tendency. APL, accoun
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 4, Pp 1-10 (2021)
Blood Cancer Journal
Blood Cancer Journal
Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and rituximab, selinexor, and ta
Autor:
Jacalyn Rosenblatt, Diane Warren, Kelly Masone, Dena Grayson, Sascha A. Tuchman, Kathleen Colson, Paul G. Richardson, Jacob P. Laubach, Robert A. Redd, Constantine S. Mitsiades
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-8 (2021)
Blood Cancer Journal
Blood Cancer Journal
Additional therapeutic options are needed for relapsed and refractory multiple myeloma (RRMM). We present data from a phase 1b, open-label, dose-escalation study (NCT01965353) of 20 patients with RRMM (median age: 63 years [range: 50–77]) and a med
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 5, Pp 1-3 (2021)
Blood Cancer Journal
Blood Cancer Journal
Background Multiple myeloma (MM) is the second most common hematologic malignancy and is associated with significant patient burden. Renal impairment has been shown to affect up to 50% of patients (pts) with MM. Renal impairment is an independent pre
Autor:
Daiichiro Hasegawa, Toshihiko Imamura, Keiko Yumura-Yagi, Yoshihiro Takahashi, Ikuya Usami, So-ichi Suenobu, Shinichiro Nishimura, Nobuhiro Suzuki, Yoshiko Hashii, Takao Deguchi, Akiko Moriya-Saito, Koji Kato, Yoshiyuki Kosaka, Masahiro Hirayama, Akihiro Iguchi, Hirohide Kawasaki, Hiroki Hori, Atsushi Sato, Tooru Kudoh, Tatsutoshi Nakahata, Megumi Oda, Junichi Hara, Keizo Horibe, for the Japan Association of Childhood Leukemia Study Group (JACLS)
Publikováno v:
Blood Cancer Journal, Vol 10, Iss 2, Pp 1-11 (2020)
Blood Cancer Journal
Blood Cancer Journal
This study was a second multicenter trial on childhood ALL by the Japan Childhood Leukemia Study Group (JACLS) to improve outcomes in non-T ALL. Between April 2002 and March 2008, 1138 children with non-T ALL were enrolled in the JACLS ALL-02 trial.
Autor:
Umberto Vitolo, Vittorio Stefoni, Pier Luigi Zinzani, Alessandro Broccoli, Paolo Corradini, Stefano Fanti, Fondazione Italiana Linfomi Onlus, Alessandro Re, Antonello Pinto, Lisa Argnani, Barbara Botto
Publikováno v:
Blood Cancer Journal, Vol 9, Iss 12, Pp 1-8 (2019)
Blood Cancer Journal
Blood Cancer Journal
Effective salvage options inducing high complete metabolic response (CMR) rates without significant toxicity are needed for Hodgkin lymphoma (HL) patients failing induction treatment and who are candidate to autologous stem cell transplantation (ASCT
Autor:
Madhav V. Dhodapkar, Jonathan L. Kaufman, Vikas Gupta, Sagar Lonial, Ajay K. Nooka, Zhengjia Chen, Jiayi Wu, David L. Jaye, Leonard T. Heffner, Craig C. Hofmeister, Subir Goyal, Nisha Joseph, Lawrence H. Boise, Timothy M. Schmidt, Benjamin G. Barwick, Leon Bernal
Publikováno v:
Blood Cancer Journal, Vol 9, Iss 12, Pp 1-13 (2019)
Blood Cancer Journal
Blood Cancer Journal
Gain of chromosome 1q (+1q) is commonly identified in multiple myeloma and has been associated with inferior outcomes. However, the prognostic implication of +1q has not been evaluated in the setting of standard triplet regimens. We retrospectively a
Autor:
Hideki Asaoku, Hiroshi Kosugi, Jae Hoon Lee, Kihyun Kim, Jin Seok Kim, Shang-Yi Huang, Chang-Ki Min, Hideo Kimura, Wee Joo Chng, Cinnie Yentia Soekojo, Brian G.M. Durie, Naoki Takezako, Shu Ling Lee, Junichi Sakamoto, Yuan Wei, Rajesh Moorakonda, Sathish Kumar Gopalakrishnan, Chandramouli Nagarajan, Chor Sang Chim, Sung Soo Yoon, Je-Jung Lee
Publikováno v:
Blood Cancer Journal, Vol 9, Iss 10, Pp 1-10 (2019)
Blood Cancer Journal
Blood Cancer Journal
Pomalidomide is a third generation immunomodulatory drug which in combination with dexamethasone, has been shown to be active in relapsed/refractory multiple myeloma. However, the data in Asian patients remain limited. We conducted a prospective phas